Astrid Morrison, MD
Radiation Oncology · Oklahoma City, OKNPI 1356348171
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 42 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by Novocure Inc. at 24.1% of the total.
Across 42 payments — averaging $19.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novocure Inc.$202
- Novartis$114
- Pharmacyclics LLC, An Abbvie Company$46
- Incyte Corporation$38
- Fortovia Therapeutics, Inc.$37
- Siemens Medical Solutions USA, Inc.$36
- plus $366 from 16 others
What the payments were for
- Food & beverage$838100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novocure Inc. | 7 | $202 |
| Novartis | 6 | $114 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $46 |
| Incyte Corporation | 2 | $38 |
| Fortovia Therapeutics, Inc. | 2 | $37 |
| Siemens Medical Solutions USA, Inc. | 2 | $36 |
| Varian Medical Systems, Inc. | 2 | $35 |
| Boston Scientific | 2 | $32 |
| AstraZeneca(2 entities) | 2 | $29 |
| EMD Serono, Inc. | 2 | $28 |
| Merck | 1 | $27 |
| Astellas Pharma US Inc | 2 | $27 |
| Progenics Pharmaceuticals, Inc. | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Coherus Oncology, Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Myriad Genetic Laboratories, Inc. | 1 | $21 |
| Caris MPI, Inc. | 1 | $19 |
| Karyopharm Therapeutics Inc. | 1 | $18 |
| Puma Biotechnology, Inc. | 1 | $13 |
| Advanced Accelerator Applications | 1 | $13 |
| Bayer | 1 | $13 |
How this compares
$838 in reported general payments places this provider in the 55th percentile of 43 radiation oncology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 47 | $839 |
| Oxycodone Hcl | 41 | $560 |
| Levothyroxine Sodium | 30 | $301 |
| Memantine Hcl | 16 | $287 |
| SsdSilver Sulfadiazine | 11 | $257 |
| Lidocaine Hcl ViscousLidocaine Hcl | 18 | $199 |
| Tamsulosin Hcl | 41 | $189 |
| Dexamethasone | 14 | $175 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 11 | $155 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Oklahoma City
- Jerry JaboinOklahoma City$14K
- Christina HensonOklahoma City$9K
- Kiran PrabhuOklahoma City$7K
- Tyler GunterOklahoma City$3K
- Mark McLaughlinOklahoma City$3K
- Shripal BhavsarOklahoma City$3K
- Leslie YonemotoOklahoma City$3K
- Gary LarsonOklahoma City$2K
- Andrea JohnstonOklahoma City$2K
- Michael ConferOklahoma City$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.